论文部分内容阅读
Ｇｅｎｔａ已开始在２００例慢性淋巴细胞白血病（ＣＬＬ）患者中进行其反义治疗药物ｇｅｎａｓｅｎｓｅ（以前称为Ｇ３１３９）的Ⅲ期临床试验。该研究将在美国、加拿大和欧洲的６０个中心展开，将就ｇｅｎａｓｅｎｓｅ作为二线药物与标准二线用药（氟达拉滨和环磷酰胺）进行
Genta has started Phase III clinical trials of its antisense drug genasense (formerly G3139) in 200 patients with chronic lymphocytic leukemia (CLL). The study, which will be conducted in 60 centers in the United States, Canada and Europe, will work on genasense as a second-line drug with standard second-line drugs (fludarabine and cyclophosphamide)